Genmab to present 16 abstracts on epcoritamab's development in B-cell malignancies at the 2024 EHA Congress in Madrid.

Genmab will present 16 abstracts at the 2024 EHA Congress in Madrid, showcasing epcoritamab's development in B-cell malignancies. Three oral presentations will highlight data on epcoritamab in relapsed/refractory follicular lymphoma, first-line DLBCL treatment, and Richter's transformation. Clinical trials will evaluate epcoritamab's safety and efficacy as a monotherapy or in combination with standard-of-care or novel therapies across multiple patient populations.

May 14, 2024
3 Articles